Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma

Inclusion Criteria: * 1\. Subjects with histological or cytological evidence of metastatic Pancreatic Adenocarcinoma, Measurable disease or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version criteria * 2\. Subjects with a life expectancy of at least 12 weeks, * 3\. Subjects with an Eastern cooperative oncology group performance status (ECOG PS) of 0, 1 or 2, * 4\. Subjects with the following adequate organ functions: * White blood cell count ≥3,000/μL (or absolute neutrophil count ≥1,500/μL) and ≤ 12,000/μL , * Platelet count ≥100.0 × 10\^9/L, * Hemoglobin ≥9.0 g/dL, * Serum creatinine ≤1.5 × the upper limit normal (ULN), * Total bilirubin ≤2.0 × ULN, * Serum aspartate transaminase levels ≤3.0 × ULN (≤5.0 × ULN in presence of liver metastases), and * Serum alanine aminotransferase levels ≤3.0 × ULN (≤5.0 × ULN in presence of liver metastases). Exclusion Criteria: * Subjects received the following previous therapies for Pancreatic Adenocarcinoma: * Surgery within the 4 weeks prior to randomization, * Radiation and chemoradiation within the 12 weeks prior to randomization, * Radiation for pain relief within the 4 weeks prior to randomization, * Gemcitabine used as a neoadjuvant or an adjuvant on surgery within the 24 weeks prior to randomization, * Chemotherapy except GEM used as an adjuvant on surgery within the 4 weeks prior to randomization, * Gemcitabine ≥600 mg/m\^2 as sensitizer for chemoradiation, * Gemcitabine \<600 mg/m\^2 as sensitizer for chemoradiation within the 12 weeks prior to randomization, * Gemcitabine used for systemic chemotherapy, or * Systemic chemotherapies except GEM within the 4 weeks prior to randomization.